Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin
Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin
The purpose of this study is to assess the safety and efficacy of repeated intravenous
 infusions of EMZ702 in combination with pegylated interferon and ribavirin in patients with
 chronic hepatitis C genotype 1.
In this study, 28 patients with chronic hepatitis C genotype 1 who have failed previous
 treatment with pegylated interferon plus ribavirin will be treated. The study treatment will
 consist of the same type and doses of pegylated interferon and ribavirin to which the patient
 failed to respond plus EMZ702. EMZ702 will be administered intravenously twice a week during
 the first 12 weeks of treatment. Thereafter and according to viral response, patients will
 continue to receive pegylated interferon and ribavirin only for up to 36 weeks.
Inclusion Criteria:

 -  Hepatitis C virus (HCV) genotype 1

 -  Previous therapy with pegylated interferon and ribavirin

 -  Documented previous treatment failure

 Exclusion Criteria:

 -  Hepatic dysfunction

 -  Coinfection with hepatitis B or HIV

 -  Other unrelated liver diseases

 -  Liver cancer